We recently published a list of 20 Stocks Insiders Were Selling In Q1 2025. In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against other stocks insiders were selling in Q1 2025.
The broader market index rose 0.2% on Tuesday amid volatility as investors awaited clarity on President Trump’s tariff policy. The market also faced pressure from weaker-than-expected economic data, including a disappointing manufacturing survey and lower-than-expected job openings, according to CNBC. The blue chip companies and Nasdaq Composite also saw modest gains, with the market continuing to react to uncertainty.
As this market uncertainty persists, insider trading often draws attention. While executive stock purchases can signal optimism, insider sales may stem from personal financial reasons or diversification needs. Executives typically follow pre-arranged plans, like 10b5-1, to ensure transparency. Insider trading offers insights but should be considered alongside a company’s financial health and market conditions.
Our Methodology
What are some of the stocks that insiders have been selling the most in the first quarter of the year? To find out, we used Insider Monkey’s insider trading stock screener, focusing only on stocks where at least five insiders had sold shares in January, February, or March. From there, we ranked the 20 stocks with the highest number of insiders selling shares.
Today, we’re focusing on stocks that insiders have been heavily selling during the first three months of the year. Using Insider Monkey’s insider trading screener, we identified stocks where at least five insider sales totaled $1 million or more. While the overall value of insider sales for these stocks may be higher, we specifically focused on sales worth $1 million or more. From the stocks that met this criterion, we selected the 20 with the highest number of insider sales of $1 million or more.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
With each stock, we note the average price per share of these purchases and the stock’s market capitalization.
A biopharmaceutical research team taking notes in front of a laboratory’s microscope.
Insmed Incorporated (NASDAQ:INSM)
Total value of insider sales in Q1: $53.02 million
Insiders with $1M+ sales: 6
Insmed Incorporated (NASDAQ:INSM) develops therapies for serious and rare diseases, with treatments like ARIKAYCE for lung infections and brensocatib for bronchiectasis in clinical trials. The Bridgewater, New Jersey-based company is also developing treatments for pulmonary hypertension and Duchenne muscular dystrophy. It is also one of the 12 most promising biotech stocks according to Wall Street analysts.
In February 2025, the FDA accepted the company’s New Drug Application (NDA) for brensocatib for patients with bronchiectasis and granted the application Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of August 12, 2025. Insmed (NASDAQ:INSM) continues to expect brensocatib will launch in the U.S. in the third quarter, if approved.
During the first quarter, seven insiders, including the CEO, COO, and CFO, sold approximately $53.02 million worth of Insmed shares at an average price of $73.79 per share. The stock now trades at $75.13 per share, having gained 8.82% year-to-date. Over the past 12 months, its shares returned 181.14%.
According to the 16 analysts Insmed (NASDAQ:INSM) stock is a “Buy,” with a price target of $94.00 per share, reports MarketBeat. The average price target suggests a potential upside of 25.05% from the latest price.
Overall, INSM ranks 20th on our list of stocks insiders were selling in Q1 2025. While we acknowledge the potential of INSM our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INSM but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
